Merck's Sacituzumab Tirumotecan Trial Shows Promising Results for Endometrial Cancer (MRK)

gurufocus.com · 2026-10-26

On October 26, 2026, Merck & Co Inc (NYSE: MRK) announced positive Phase 3 clinical trial results for sacituzumab tirumotecan (sac-TMT), demonstrating significa

Read the full story at gurufocus.com →